Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Emmessar Biotech & Nutrition Ltd, at its meeting held on April 24, 2025, approved the audited standalone financial results for the year ended March 31, 2025. Revenue from Operations rose modestly to Rs. 61.09 lakhs from Rs. 55.52 lakhs in the previous year (~10% growth), while Total Income stood at Rs. 261.96 lakhs (vs Rs. 254.73 lakhs). Total expenses declined to Rs. 166.14 lakhs from Rs. 173.47 lakhs, helping Profit Before Tax grow to Rs. 95.82 lakhs (vs Rs. 81.26 lakhs). However, Net Profit after tax fell sharply to Rs. 31.61 lakhs (from Rs. 65.11 lakhs, ~51% decline) due to a much higher total tax expense of Rs. 64.20 lakhs. EPS dropped to Rs. 0.61 from Rs. 1.28. Statutory auditor V. Nagarajan & Co. issued an unmodified (clean) opinion. The company operates in two segments — Healthcare and Rent on leasehold land — and reported no investor complaints for the quarter.
Operating performance improved (lower costs, higher PBT), but a sharp jump in tax burden cut net profit and EPS by more than half compared to last year. The clean auditor opinion is reassuring, but the steep PAT decline despite revenue growth is a negative signal for shareholders.